Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Frequency of compound genotypes associated with beta-blocker efficacy in congestive heart failure.

Pharmacogenomics - 1 Jul 2004

Lanfear David E, Marsh Sharon, Cresci Sharon, Spertus John A, McLeod Howard L

Abstract excerpt

An important practical problem in pharmacogenetics is the integration of compound genotypes into individualized therapy. Polymorphisms in the genes encoding the angiotensin-converting enzyme, and beta(1)- and beta(2)-adrenoceptors have been identified as predictors of 'good response' to beta-adre...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adrenergic beta-Antagonists
Share to Black or African American
Share to Chi-Square Distribution

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Europe

Share to Gene Frequency

Share to Genotype

Share to Heart Failure

Share to White People

Source

Identifiers

PMID: 15212591
DOI: 10.1517/14622416.5.5.553

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026. Prepared record publication-15212591-2026-09-01.1. Manifest publication-graph-cohort-2026-09-01.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Frequency of compound genotypes associated with beta-blocker efficacy in congestive heart failure.PMID 15212591Read ↗

Pharmacogenetics of heart failure: evidence, opportunities, and challenges for cardiovascular pharmacogenomics.Semantic proximity Read ↗

The future of pharmacogenetics in the treatment of heart failure.Semantic proximity Read ↗

State of play of pharmacogenetics and personalized medicine in heart failure.Semantic proximity Read ↗

Emerging role of pharmacogenomics in heart failure.Semantic proximity Read ↗

Pharmacogenomics of heart failure.Semantic proximity Read ↗

β-adrenergic receptor polymorphisms in susceptibility, response to treatment and prognosis in heart failure: implication of ethnicity.Semantic proximity Read ↗

Pharmacogenomics of beta1-adrenergic receptor polymorphisms in heart failure.Semantic proximity Read ↗

Genetic tailoring of pharmacotherapy in heart failure: optimize the old, while we wait for something new.Semantic proximity Read ↗

Association of beta-adrenergic receptor polymorphisms and mortality in carvedilol-treated chronic heart-failure patients.Semantic proximity Read ↗

Association between Adrenergic Receptor Genotypes and Beta-Blocker Dose in Heart Failure Patients: Analysis from the HF-ACTION DNA SubstudySemantic proximity Read ↗

Beta2-adrenergic receptor genotype predicts survival: implications and future directions.Semantic proximity Read ↗

The Beta-Blocker Pharmacogenetic Puzzle: More Pieces of Evidence for Pharmacodynamic Candidate Variants.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.